Who
John J. Monahan
Director
Company insider
Files Form 4 as: Director, Theriva Biologics; Director, NightHawk Biosciences; Director, Anixa Biosciences.
In numbers
- Trades disclosed
- 38
- Buys
- 1
- Sells
- 0
- Bought
- $3,798
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 29 Jul 2013
- Last trade
- 5 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jan 2026filed 6 Jan 2026 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 5 Jan 2026filed 6 Jan 2026 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 29 Apr 2025filed 1 May 2025 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 14 Dec 2023filed 15 Dec 2023 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 15 Dec 2022filed 16 Dec 2022 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 7 Dec 2022filed 9 Dec 2022 | NightHawk Biosciencesoption or derivative | SEC FORM 4 Code A | —101,960 at $0.00 | filing |
| 30 Dec 2021filed 3 Jan 2022 | Heat Biologicsoption or derivative | SEC FORM 4 Code J | —32,467 at $0.00 | filing |
| 30 Dec 2021filed 3 Jan 2022 | Heat Biologicsoption or derivative | SEC FORM 4 Code A | —32,467 at $0.00 | filing |
| 23 Dec 2021filed 27 Dec 2021 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 13 Dec 2021filed 15 Dec 2021 | Heat Biologicsoption or derivative | SEC FORM 4 Code A | —32,467 at $0.00 | filing |
| 4 Jan 2021filed 6 Jan 2021 | Heat Biologicsoption or derivative | SEC FORM 4 Code A | —65,217 at $0.00 | filing |
| 30 Dec 2020filed 31 Dec 2020 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 13 Aug 2020filed 17 Aug 2020 | ANIX Anixa Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 2 Jan 2020filed 2 Jan 2020 | Heat Biologicsoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 23 Oct 2019filed 24 Oct 2019 | ANIX Anixa Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 20 Sep 2019filed 20 Sep 2019 | ANIX Anixa Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —6,000 | filing |
| 20 Sep 2019filed 20 Sep 2019 | ANIX Anixa Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 | filing |
| 20 Sep 2019filed 20 Sep 2019 | ANIX Anixa Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —12,000 | filing |
| 20 Sep 2019filed 20 Sep 2019 | ANIX Anixa Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 | filing |
| 29 Apr 2019filed 29 Apr 2019 | ANIX Anixa BiosciencesBiotechnology | SEC FORM 4 Bought | $3,798900 at $4.22 | filing |
News
Immatics (NASDAQ:IMTX) & Anixa Biosciences (NASDAQ:ANIX) Financial ComparisonANIX · dailypolitical.com · 16 Oct 2026Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer VaccineANIX · hawaiitelegraph.com · 13 Oct 2026
0 headlines in the last 90 days name John J. Monahan; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.